Cardiometabolic Outcomes, Mechanisms and approach to prevention of Dolutegravir Associated Weight Gain In South Africa
The following grant was awarded by, is supported by, is administered by or is in partnership with the Fogarty International Center at the U.S. National Institutes of Health (NIH).
Funding Fogarty Program
HIV-associated Noncommunicable Diseases Research at LMIC Institutions
Project Information in NIH RePORTER
Cardiometabolic Outcomes, Mechanisms and approach to prevention of Dolutegravir Associated Weight Gain In South Africa
Principal Institution
University of Pittsburgh
Principal Investigator(s) (PI)
Nachega, Jean Bisimwa; Kengne, Andre Pascal
Project Contact Information
jbn16@pitt.edu
Year(s) Awarded
2020–2022
Country
South Africa
Project Description
DTG-based ART regimens are poised to become the backbone for contemporary ART in South Africa, where the vast majority of PLWH reside. Our project study focuses on the not only the effects of dolutegravir on weight gain, changes in body composition and fat distribution, accumulation of liver fat, and blood markers of cardiometabolic risk, but the feasibility of a possible intervention. Our study will therefore provide critical data that will elucidate the mechanisms and health consequences of DTG-associated weight gain to inform the development of screening/prevention strategies, which could influence clinical practice and be implemented and scaled-up globally for PLWH on DTG-containing ART regimens.
Related World Regions / Countries
Related Global Health Research Topics